Le informazioni sugli articoli di fonte ISI sono coperte da copyright

Per ulteriori informazioni selezionare i riferimenti di interesse.

1. Romano, L; Venturi, G; Vivarelli, A; Galli, L; Zazzi, M
   Detection of a drug-resistant human immunodeficiency virus variant in a newly infected heterosexual couple
   CLINICAL INFECTIOUS DISEASES
   
   L. Romano et al., "Detection of a drug-resistant human immunodeficiency virus variant in a newly infected heterosexual couple", CLIN INF D, 34(1), 2002, pp. 116-117
2. Raulin, J
   Human immunodeficiency virus and host cell lipids. Interesting pathways inresearch for a new HIV therapy
   PROGRESS IN LIPID RESEARCH
   
   J. Raulin, "Human immunodeficiency virus and host cell lipids. Interesting pathways inresearch for a new HIV therapy", PROG LIPID, 41(1), 2002, pp. 27-65
3. Devereux, HL; Burke, A; Lee, CA; Johnson, MA
   In vivo HIV-1 compartmentalisation: Drug resistance-associated mutation distribution
   JOURNAL OF MEDICAL VIROLOGY
   
   H.L. Devereux et al., "In vivo HIV-1 compartmentalisation: Drug resistance-associated mutation distribution", J MED VIROL, 66(1), 2002, pp. 8-12
4. Brincat, JL; Pfeiffer, JK; Telesnitsky, A
   RNase H activity is required for high-frequency repeat deletion during moloney murine leukemia virus replication
   JOURNAL OF VIROLOGY
   
   J.L. Brincat et al., "RNase H activity is required for high-frequency repeat deletion during moloney murine leukemia virus replication", J VIROLOGY, 76(1), 2002, pp. 88-95
5. Casimiro, DR; Tang, AM; Perry, HC; Long, RS; Chen, MC; Heidecker, GJ; Davies, ME; Freed, DC; Persaud, NV; Dubey, S; Smith, JG; Havlir, D; Richman, D; Chastain, MA; Simon, AJ; Fu, TM; Emini, EA; Shiver, JW
   Vaccine-induced immune responses in rodents and nonhuman primates by use of a humanized human immunodeficiency virus type 1 pol gene
   JOURNAL OF VIROLOGY
   
   D.R. Casimiro et al., "Vaccine-induced immune responses in rodents and nonhuman primates by use of a humanized human immunodeficiency virus type 1 pol gene", J VIROLOGY, 76(1), 2002, pp. 185-194
6. Lawler, JF; Merkulov, GV; Boeke, JD
   A nucleocapsid functionality contained within the amino terminus of the Ty1 protease that is distinct and separable from proteolytic activity
   JOURNAL OF VIROLOGY
   
   J.F. Lawler et al., "A nucleocapsid functionality contained within the amino terminus of the Ty1 protease that is distinct and separable from proteolytic activity", J VIROLOGY, 76(1), 2002, pp. 346-354
7. Lacroix, J; Doeberitz, MV
   Technical aspects of minimal residual disease detection in carcinoma patients
   SEMINARS IN SURGICAL ONCOLOGY
   
   J. Lacroix e M.V. Doeberitz, "Technical aspects of minimal residual disease detection in carcinoma patients", SEM SURG ON, 20(4), 2001, pp. 252-264
8. Kienle, P; Koch, M
   Minimal residual disease in gastrointestinal cancer
   SEMINARS IN SURGICAL ONCOLOGY
   
   P. Kienle e M. Koch, "Minimal residual disease in gastrointestinal cancer", SEM SURG ON, 20(4), 2001, pp. 282-293
9. Ghossein, RA; Bhattacharya, S
   Molecular detection and characterization of circulating tumor cells and micrometastases in prostatic, urothelial, and renal cell carcinomas
   SEMINARS IN SURGICAL ONCOLOGY
   
   R.A. Ghossein e S. Bhattacharya, "Molecular detection and characterization of circulating tumor cells and micrometastases in prostatic, urothelial, and renal cell carcinomas", SEM SURG ON, 20(4), 2001, pp. 304-311
10. Grandin, N; Charbonneau, M
    Hsp90 levels affect telomere length in yeast
    MOLECULAR GENETICS AND GENOMICS
    
    N. Grandin e M. Charbonneau, "Hsp90 levels affect telomere length in yeast", MOL GENET G, 265(1), 2001, pp. 126-134
11. Pifferi, A; Camalli, M; Silvestri, R; De Martino, G; Massa, S; Artico, M
    1-Amino-6-chloro-2-(1H-pyrrol-2-yl)benzimidazole (RS 1350)
    ACTA CRYSTALLOGRAPHICA SECTION E-STRUCTURE REPORTS ONLINE
    
    A. Pifferi et al., "1-Amino-6-chloro-2-(1H-pyrrol-2-yl)benzimidazole (RS 1350)", ACT CRYST E, 57, 2001, pp. o819-o821
12. Cho, YK; Sung, H; Lee, HJ; Joo, CH; Cho, GJ
    Long-term intake of Korean red ginseng in HIV-1-infected patients: development of resistance mutation to zidovudine is delayed
    INTERNATIONAL IMMUNOPHARMACOLOGY
    
    Y.K. Cho et al., "Long-term intake of Korean red ginseng in HIV-1-infected patients: development of resistance mutation to zidovudine is delayed", INT IMMUNO, 1(7), 2001, pp. 1295-1305
13. Olivero, OA; Reddy, MK; Pietras, SM; Poirier, MC
    Plasma drug levels compared with DNA incorporation of 3'-azido-3'-deoxythymidine (AZT) in adult cynomolgus (Macaca fascicularis) monkeys
    EXPERIMENTAL BIOLOGY AND MEDICINE
    
    O.A. Olivero et al., "Plasma drug levels compared with DNA incorporation of 3'-azido-3'-deoxythymidine (AZT) in adult cynomolgus (Macaca fascicularis) monkeys", EXP BIOL ME, 226(5), 2001, pp. 446-449
14. Lee, K; Chong, YH; Chu, CK
    Understanding the mode of action of L-nucleosides as antiviral agents: A molecular modeling approach
    NUCLEOSIDES NUCLEOTIDES & NUCLEIC ACIDS
    
    K. Lee et al., "Understanding the mode of action of L-nucleosides as antiviral agents: A molecular modeling approach", NUCLEOS NUC, 20(4-7), 2001, pp. 385-388
15. Bryant, ML; Bridges, EG; Placidi, L; Faraj, A; Loi, AG; Pierra, C; Dukhan, D; Gosselin, G; Imbach, JL; Hernandez, B; Juodawlkis, A; Tennant, B; Korba, B; Cote, P; Cretton-Scott, E; Schinazi, RF; Sommadossi, JP
    Anti-HBV specific beta-L-2 '-deoxynucleosides
    NUCLEOSIDES NUCLEOTIDES & NUCLEIC ACIDS
    
    M.L. Bryant et al., "Anti-HBV specific beta-L-2 '-deoxynucleosides", NUCLEOS NUC, 20(4-7), 2001, pp. 597-607
16. Naeger, LK; Margot, NA; Miller, MD
    Tenofovir (PMPA) is less susceptible to pyrophosphorolysis and nucleotide-dependent chain-terminator removal than zidovudine or stavudine
    NUCLEOSIDES NUCLEOTIDES & NUCLEIC ACIDS
    
    L.K. Naeger et al., "Tenofovir (PMPA) is less susceptible to pyrophosphorolysis and nucleotide-dependent chain-terminator removal than zidovudine or stavudine", NUCLEOS NUC, 20(4-7), 2001, pp. 635-639
17. Lobaton, E; Velazquez, S; Perez-Perez, MJ; Jimeno, ML; San-Felix, A; De Clercq, E; Balzarini, J; Camarasa, MJ
    "Second generation" of TSAO compounds directed against HIV-1 TSAO-resistant strains
    NUCLEOSIDES NUCLEOTIDES & NUCLEIC ACIDS
    
    E. Lobaton et al., ""Second generation" of TSAO compounds directed against HIV-1 TSAO-resistant strains", NUCLEOS NUC, 20(4-7), 2001, pp. 707-710
18. Lobaton, E; Velazquez, S; San-Felix, A; De Clercq, E; Balzarini, J; Camarasa, MJ
    4 ''-H-TSAO-T, a novel prototype in the HIV-1 specific TSAO family
    NUCLEOSIDES NUCLEOTIDES & NUCLEIC ACIDS
    
    E. Lobaton et al., "4 ''-H-TSAO-T, a novel prototype in the HIV-1 specific TSAO family", NUCLEOS NUC, 20(4-7), 2001, pp. 711-714
19. Noronha, AM; Arion, D; Parniak, MA; Damha, MJ
    Effect of substituting arabinonucleosides for deoxynucleotides in the DNA priming strand on the polymerase action of HIV-1 RT
    NUCLEOSIDES NUCLEOTIDES & NUCLEIC ACIDS
    
    A.M. Noronha et al., "Effect of substituting arabinonucleosides for deoxynucleotides in the DNA priming strand on the polymerase action of HIV-1 RT", NUCLEOS NUC, 20(4-7), 2001, pp. 1205-1209
20. Yamaguchi, T; Yamada, R; Tomikawa, A; Shudo, K; Saito, M; Ishikawa, F; Saneyoshi, M
    Inhibition of human telomerase by L-enantiomers of natural 2 '-deoxyribonucleoside 5 '-triphosphates
    NUCLEOSIDES NUCLEOTIDES & NUCLEIC ACIDS
    
    T. Yamaguchi et al., "Inhibition of human telomerase by L-enantiomers of natural 2 '-deoxyribonucleoside 5 '-triphosphates", NUCLEOS NUC, 20(4-7), 2001, pp. 1243-1246
21. Akeb, F; Creminon, C; Grassi, J; Guedj, R; Duval, D
    The production and evaluation of antibodies for enzyme immunoassay of AZTTP
    NUCLEOSIDES NUCLEOTIDES & NUCLEIC ACIDS
    
    F. Akeb et al., "The production and evaluation of antibodies for enzyme immunoassay of AZTTP", NUCLEOS NUC, 20(3), 2001, pp. 243-250
22. Belostotskii, AM; Keren-Yeshuah, H; Lexner, J; Hassner, A
    New 3 '-deoxythymidines bearing a nucleophilic 3 '-substituent
    NUCLEOSIDES NUCLEOTIDES & NUCLEIC ACIDS
    
    A.M. Belostotskii et al., "New 3 '-deoxythymidines bearing a nucleophilic 3 '-substituent", NUCLEOS NUC, 20(1-2), 2001, pp. 93-101
23. Kyriakides, TC; Heimer, RR
    Development and application of a genotypic AZT resistance assay - Quantitative assessment of the resistance profile of clinical samples and the relative predictive ability of a resistance index
    JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
    
    T.C. Kyriakides e R.R. Heimer, "Development and application of a genotypic AZT resistance assay - Quantitative assessment of the resistance profile of clinical samples and the relative predictive ability of a resistance index", J ACQ IMM D, 28(3), 2001, pp. 211-220
24. Stuart, JWTC; Wensing, AMJ; Kovacs, C; Righart, M; de Jong, D; Kaye, S; Schuurman, R; Visser, CJT; Boucher, CAB
    Transient relapses ("blips") of plasma HIV RNA levels during HAART are associated with drug resistance
    JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
    
    J.W.T.C. Stuart et al., "Transient relapses ("blips") of plasma HIV RNA levels during HAART are associated with drug resistance", J ACQ IMM D, 28(2), 2001, pp. 105-113
25. Rakotoambinina, B; Medioni, J; Rabian, C; Jubault, V; Jais, JP; Viard, JP
    Lipodystrophic syndromes and hyperlipidemia in a cohort of HIV-1-infected patients receiving triple combination antiretroviral therapy with a protease inhibitor
    JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
    
    B. Rakotoambinina et al., "Lipodystrophic syndromes and hyperlipidemia in a cohort of HIV-1-infected patients receiving triple combination antiretroviral therapy with a protease inhibitor", J ACQ IMM D, 27(5), 2001, pp. 443-449
26. Miller, MD; Margot, NA; Lamy, PD; Fuller, MD; Anton, KE; Mulato, AS; Cherrington, JM
    Adefovir and tenofovir susceptibilities of HIV-1 after 24 to 48 weeks of adefovir dipivoxil therapy: Genotypic and phenotypic analyses of study GS-96-408
    JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
    
    M.D. Miller et al., "Adefovir and tenofovir susceptibilities of HIV-1 after 24 to 48 weeks of adefovir dipivoxil therapy: Genotypic and phenotypic analyses of study GS-96-408", J ACQ IMM D, 27(5), 2001, pp. 450-458
27. Roberts, DE; Ribeiro, RM
    Comparison of different treatment regimens for the emergence of new resistance under therapy
    JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
    
    D.E. Roberts e R.M. Ribeiro, "Comparison of different treatment regimens for the emergence of new resistance under therapy", J ACQ IMM D, 27(4), 2001, pp. 331-335
28. Shulman, NS; Machekano, RA; Shafer, RW; Winters, MA; Zolopa, AR; Liou, SH; Hughes, M; Katzenstein, DA
    Genotypic correlates of a virologic response to stavudine after zidovudinemonotherapy
    JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
    
    N.S. Shulman et al., "Genotypic correlates of a virologic response to stavudine after zidovudinemonotherapy", J ACQ IMM D, 27(4), 2001, pp. 377-380
29. Bogner, JR; Vielhauer, V; Beckmann, RA; Michl, G; Wille, L; Salzberger, B; Goebel, FD
    Stavudine versus zidovudine and the development of lipodystrophy
    JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
    
    J.R. Bogner et al., "Stavudine versus zidovudine and the development of lipodystrophy", J ACQ IMM D, 27(3), 2001, pp. 237-244
30. Ungsedhapand, C; Kroon, EDMB; Suwanagool, S; Ruxrungtham, K; Yimsuan, N; Sonjai, A; Ubolyam, S; Buranapraditkun, S; Tiengrim, S; Pakker, N; Kunanusont, C; Lange, JMA; Cooper, DA; Phanuphak, P
    A randomized, open-label, comparative trial of zidovudine plus lamivudine versus zidovudine plus lamivudine plus didanosine in antiretroviral-naive HIV-1-infected Thai patients
    JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
    
    C. Ungsedhapand et al., "A randomized, open-label, comparative trial of zidovudine plus lamivudine versus zidovudine plus lamivudine plus didanosine in antiretroviral-naive HIV-1-infected Thai patients", J ACQ IMM D, 27(2), 2001, pp. 116-123
31. Mulligan, K; Tai, VW; Algren, H; Abrams, DI; Leiser, RJ; Lo, JC; Schambelan, M
    Altered fat distribution in HIV-positive men on nucleoside analog reverse transcriptase inhibitor therapy
    JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
    
    K. Mulligan et al., "Altered fat distribution in HIV-positive men on nucleoside analog reverse transcriptase inhibitor therapy", J ACQ IMM D, 26(5), 2001, pp. 443-448
32. Weidle, PJ; Kityo, CM; Mugyenyi, P; Downing, R; Kebba, A; Pieniazek, D; Respess, R; Hertogs, K; De Vroey, V; Dehertogh, P; Bloor, S; Larder, B; Lackritz, E
    Resistance to antiretroviral therapy among patients in Uganda
    JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
    
    P.J. Weidle et al., "Resistance to antiretroviral therapy among patients in Uganda", J ACQ IMM D, 26(5), 2001, pp. 495-500
33. Duwe, S; Brunn, M; Altmann, D; Hamouda, O; Schmidt, B; Walter, H; Pauli, G; Kucherer, C
    Frequency of genotypic and phenotypic drug-resistant HIV-1 among therapy-naive patients of the German Seroconverter Study
    JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
    
    S. Duwe et al., "Frequency of genotypic and phenotypic drug-resistant HIV-1 among therapy-naive patients of the German Seroconverter Study", J ACQ IMM D, 26(3), 2001, pp. 266-273
34. Briones, C; Perez-Olmeda, M; Rodriguez, C; del Romero, J; Hertogs, K; Soriano, V
    Primary genotypic and phenotypic HIV-1 drug resistance in recent seroconverters in Madrid
    JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
    
    C. Briones et al., "Primary genotypic and phenotypic HIV-1 drug resistance in recent seroconverters in Madrid", J ACQ IMM D, 26(2), 2001, pp. 145-150
35. Rousseau, MN; Vergne, L; Montes, B; Peeters, M; Reynes, J; Delaporte, E; Segondy, M
    Patterns of resistance mutations to antiretroviral drugs in extensively treated HIV-1-Infected patients with failure of highly active antiretroviral therapy
    JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
    
    M.N. Rousseau et al., "Patterns of resistance mutations to antiretroviral drugs in extensively treated HIV-1-Infected patients with failure of highly active antiretroviral therapy", J ACQ IMM D, 26(1), 2001, pp. 36-43
36. Becker, SL; Raffanti, SR; Hansen, NI; Fusco, JS; Fusco, GP; Slatko, GH; Igboko, EF; Graham, NMH
    Zidovudine and stavudine sequencing in HIV treatment planning: Findings from the CHORUS HIV cohort
    JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
    
    S.L. Becker et al., "Zidovudine and stavudine sequencing in HIV treatment planning: Findings from the CHORUS HIV cohort", J ACQ IMM D, 26(1), 2001, pp. 72-81
37. Reisler, RB; Thea, DM; Pliner, V; Green, T; Lee, F; Nesheim, S; Brown, T; Kalish, M; Folks, TM; Heneine, W
    Early detection of reverse transcriptase activity in plasma of neonates infected with HIV-1: A comparative analysis with RNA-based and DNA-based testing using polymerase chain reaction
    JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
    
    R.B. Reisler et al., "Early detection of reverse transcriptase activity in plasma of neonates infected with HIV-1: A comparative analysis with RNA-based and DNA-based testing using polymerase chain reaction", J ACQ IMM D, 26(1), 2001, pp. 93-102
38. Demeter, L; Haubrich, R
    Phenotypic and genotypic resistance assays: Methodology, reliability, and interpretations
    JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
    
    L. Demeter e R. Haubrich, "Phenotypic and genotypic resistance assays: Methodology, reliability, and interpretations", J ACQ IMM D, 26, 2001, pp. S3-S9
39. Loveday, C
    Nucleoside reverse transcriptase inhibitor resistance
    JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
    
    C. Loveday, "Nucleoside reverse transcriptase inhibitor resistance", J ACQ IMM D, 26, 2001, pp. S10-S24
40. Miller, V
    Resistance to protease inhibitors
    JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
    
    V. Miller, "Resistance to protease inhibitors", J ACQ IMM D, 26, 2001, pp. S34-S50
41. Maijgren-Steffensson, C; Sonnerborg, A; Vahlne, A; Britton, S; Larsson, S; Ahrlund-Richter, L
    Smaller amounts of antiretroviral drugs are needed when combined with an active ribozyme against HIV-1
    MOLECULAR THERAPY
    
    C. Maijgren-Steffensson et al., "Smaller amounts of antiretroviral drugs are needed when combined with an active ribozyme against HIV-1", MOL THER, 3(4), 2001, pp. 531-535
42. Paquette, LA; Bibart, RT; Seekamp, CK; Kahane, AL
    Spirocyclic restriction of nucleosides. Synthesis of the first exemplary syn-1-oxaspiro[4.4]nonanyl member
    ORGANIC LETTERS
    
    L.A. Paquette et al., "Spirocyclic restriction of nucleosides. Synthesis of the first exemplary syn-1-oxaspiro[4.4]nonanyl member", ORG LETT, 3(25), 2001, pp. 4039-4041
43. Aggarwal, VK; de Vicente, J; Bonnert, RV
    Catalytic cyclopropanation of alkenes using diazo compounds generated in situ. A novel route to 2-arylcyclopropylamines
    ORGANIC LETTERS
    
    V.K. Aggarwal et al., "Catalytic cyclopropanation of alkenes using diazo compounds generated in situ. A novel route to 2-arylcyclopropylamines", ORG LETT, 3(17), 2001, pp. 2785-2788
44. Hiyama, E; Hiyama, K; Yokoyama, T; Shay, JW
    Immunohistochemical detection of telomerase (hTERT) protein in human cancer tissues and a subset of cells in normal tissues
    NEOPLASIA
    
    E. Hiyama et al., "Immunohistochemical detection of telomerase (hTERT) protein in human cancer tissues and a subset of cells in normal tissues", NEOPLASIA, 3(1), 2001, pp. 17-26
45. Vekshin, N; Savintsev, I; Kovalev, A; Yelemessov, R; Wadkins, RM
    Solvatochromism of the excitation and emission spectra of 7-aminoactinomycin D: Implications for drug recognition of DNA secondary structures
    JOURNAL OF PHYSICAL CHEMISTRY B
    
    N. Vekshin et al., "Solvatochromism of the excitation and emission spectra of 7-aminoactinomycin D: Implications for drug recognition of DNA secondary structures", J PHYS CH B, 105(35), 2001, pp. 8461-8467
46. Olsen, AG; Nielsen, C; Wengel, J
    Synthesis and evaluation of anti-HIV activity of 3-azido-4-(hydroxymethyl)tetrahydrofuran derivatives containing 2-(thymin-1-yl)methyl, 2-(cytosin-1-yl)methyl or 2-(adenin-9-yl)methyl substituents - a new series of AZT analogues
    JOURNAL OF THE CHEMICAL SOCIETY-PERKIN TRANSACTIONS 1
    
    A.G. Olsen et al., "Synthesis and evaluation of anti-HIV activity of 3-azido-4-(hydroxymethyl)tetrahydrofuran derivatives containing 2-(thymin-1-yl)methyl, 2-(cytosin-1-yl)methyl or 2-(adenin-9-yl)methyl substituents - a new series of AZT analogues", J CHEM S P1, (8), 2001, pp. 900-904
47. Negroni, M; Buc, H
    Retroviral recombination: what drives the switch?
    NATURE REVIEWS MOLECULAR CELL BIOLOGY
    
    M. Negroni e H. Buc, "Retroviral recombination: what drives the switch?", NAT REV MOL, 2(2), 2001, pp. 151-155
48. Holmes, EC
    On the origin and evolution of the human immunodeficiency virus (HIV)
    BIOLOGICAL REVIEWS
    
    E.C. Holmes, "On the origin and evolution of the human immunodeficiency virus (HIV)", BIOL REV, 76(2), 2001, pp. 239-254
49. Huang, A; Hindle, KS; Tsavellas, G
    Colorectal cancer surveillance post-surgery
    HOSPITAL MEDICINE
    
    A. Huang et al., "Colorectal cancer surveillance post-surgery", HOSP MED, 62(8), 2001, pp. 490-491
50. Iorgulescu, DG; Kiroff, GK
    Minimal residual marrow disease: Detection and significance of isolated tumour cells in bone marrow
    ANZ journal of surgery
    
    D.G. Iorgulescu e G.K. Kiroff, "Minimal residual marrow disease: Detection and significance of isolated tumour cells in bone marrow", AUST NZ J S, 71(6), 2001, pp. 365-376
51. Buck, C; Walsh, C; Davis, R; Toumadje, A; Kusamoto, K; Helmrich, A; Chapline, C; Mericko, P; Barnes, D
    Cell cultures and retroviral particles from a tumor of a moray eel
    MARINE BIOTECHNOLOGY
    
    C. Buck et al., "Cell cultures and retroviral particles from a tumor of a moray eel", MAR BIOTEC, 3, 2001, pp. S196-S202
52. Bianco, A; Celona, D; Di Rita, S; Guiso, M; Melchioni, C; Umani, F
    Chiral synthons from the iridoid glucoside antirrhinoside - Synthesis of acarbocyclic homonucleoside analogue
    EUROPEAN JOURNAL OF ORGANIC CHEMISTRY
    
    A. Bianco et al., "Chiral synthons from the iridoid glucoside antirrhinoside - Synthesis of acarbocyclic homonucleoside analogue", EUR J ORG C, (21), 2001, pp. 4061-4066
53. Surnmerer, D; Marx, A
    DNA polymerase selectivity: Sugar interactions monitored with high-fidelity nucleotides
    ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
    
    D. Surnmerer e A. Marx, "DNA polymerase selectivity: Sugar interactions monitored with high-fidelity nucleotides", ANGEW CHEM, 40(19), 2001, pp. 3693
54. Ettorre, A; Silvestri, R; Artico, M; Massa, S; La Colla, P
    Crystal structure of 7-chloropyrrolo[1,2-b][1,2,5]benzothiadiazepin-10(11H)-one-5,5-dioxide, C11H7N2O3ClS
    ZEITSCHRIFT FUR KRISTALLOGRAPHIE-NEW CRYSTAL STRUCTURES
    
    A. Ettorre et al., "Crystal structure of 7-chloropyrrolo[1,2-b][1,2,5]benzothiadiazepin-10(11H)-one-5,5-dioxide, C11H7N2O3ClS", Z KRIST-NEW, 216(1), 2001, pp. 57-58
55. Tasara, T; Hottiger, MO; Hubscher, U
    Functional genomics in HIV-1 virus replication: Protein-protein interactions as a basis for recruiting the host cell machinery for viral propagation
    BIOLOGICAL CHEMISTRY
    
    T. Tasara et al., "Functional genomics in HIV-1 virus replication: Protein-protein interactions as a basis for recruiting the host cell machinery for viral propagation", BIOL CHEM, 382(7), 2001, pp. 993-999
56. Flepp, M; Schiffer, V; Weber, R; Hirschel, B
    Modern anti-HIV therapy
    SWISS MEDICAL WEEKLY
    
    M. Flepp et al., "Modern anti-HIV therapy", SWISS MED W, 131(15-16), 2001, pp. 207-213
57. Wilhelm, M; Wilhelm, FX
    Reverse transcription of retroviruses and LTR retrotransposons
    CELLULAR AND MOLECULAR LIFE SCIENCES
    
    M. Wilhelm e F.X. Wilhelm, "Reverse transcription of retroviruses and LTR retrotransposons", CELL MOL L, 58(9), 2001, pp. 1246-1262
58. Pereira, AS; Tidwell, RR
    Separation methods for nucleoside analogues used for treatment of HIV-1 infection
    JOURNAL OF CHROMATOGRAPHY B
    
    A.S. Pereira e R.R. Tidwell, "Separation methods for nucleoside analogues used for treatment of HIV-1 infection", J CHROMAT B, 764(1-2), 2001, pp. 327-347
59. Sarasa-Nacenta, M; Lopez-Pua, Y; Lopez-Cortes, LF; Mallolas, J; Gatell, JM; Carne, X
    Determination of efavirenz in human plasma by high-performance liquid chromatography with ultraviolet detection
    JOURNAL OF CHROMATOGRAPHY B
    
    M. Sarasa-Nacenta et al., "Determination of efavirenz in human plasma by high-performance liquid chromatography with ultraviolet detection", J CHROMAT B, 763(1-2), 2001, pp. 53-59
60. Gahan, ME; Miller, F; Lewin, SR; Cherry, CL; Hoy, JF; Mijch, A; Rosenfeldt, F; Wesselingh, SL
    Quantification of mitochondrial DNA in peripheral blood mononuclear cells and subcutaneous fat using real-time polymerase chain reaction
    JOURNAL OF CLINICAL VIROLOGY
    
    M.E. Gahan et al., "Quantification of mitochondrial DNA in peripheral blood mononuclear cells and subcutaneous fat using real-time polymerase chain reaction", J CLIN VIRO, 22(3), 2001, pp. 241-247
61. Arens, M
    Clinically relevant sequence-based genotyping of HBV, HCV, CMV, and HIV
    JOURNAL OF CLINICAL VIROLOGY
    
    M. Arens, "Clinically relevant sequence-based genotyping of HBV, HCV, CMV, and HIV", J CLIN VIRO, 22(1), 2001, pp. 11-29
62. Merour, JY; Joseph, B
    Synthesis and reactivity of 7-azaindoles (1H-pyrrolo[2,3-b]pyridine)
    CURRENT ORGANIC CHEMISTRY
    
    J.Y. Merour e B. Joseph, "Synthesis and reactivity of 7-azaindoles (1H-pyrrolo[2,3-b]pyridine)", CURR ORG CH, 5(5), 2001, pp. 471-506
63. Kislyi, VV; Samet, AV; Semenov, VV
    The utility of nitroacetic acid and its derivatives in the synthesis of heterocycles
    CURRENT ORGANIC CHEMISTRY
    
    V.V. Kislyi et al., "The utility of nitroacetic acid and its derivatives in the synthesis of heterocycles", CURR ORG CH, 5(5), 2001, pp. 553-570
64. Ferrer, M; Sanchez-Lamar, A; Fuentes, JL; Barbe, J; Llagostera, M
    Studies on the antimutagenesis of Phyllanthus orbicularis: mechanisms involved against aromatic amines
    MUTATION RESEARCH-GENETIC TOXICOLOGY AND ENVIRONMENTAL MUTAGENESIS
    
    M. Ferrer et al., "Studies on the antimutagenesis of Phyllanthus orbicularis: mechanisms involved against aromatic amines", MUT RES-GTE, 498(1-2), 2001, pp. 99-105
65. Sumida, T; Hamakawa, H
    Telomerase and oral cancer
    ORAL ONCOLOGY
    
    T. Sumida e H. Hamakawa, "Telomerase and oral cancer", ORAL ONCOL, 37(4), 2001, pp. 333-340
66. Kijak, GH; Avila, MM; Salomon, H
    Mother-to-child transmission of drug-resistant HIV
    DRUG RESISTANCE UPDATES
    
    G.H. Kijak et al., "Mother-to-child transmission of drug-resistant HIV", DRUG RESIST, 4(1), 2001, pp. 29-37
67. Plettenberg, A; Albrecht, D; Lorenzen, T; Paech, V; Petersen, H; Fenner, T; Meyer, T; Arndt, R; Hertogs, K; Pauwels, R; Weitzel, T; Stoehr, A
    Resistance analyses in HIV infected patients with a history of multiple antiretroviral treatment regimens
    SEXUALLY TRANSMITTED INFECTIONS
    
    A. Plettenberg et al., "Resistance analyses in HIV infected patients with a history of multiple antiretroviral treatment regimens", SEX TRANS I, 77(6), 2001, pp. 449-452
68. White, AJ
    Mitochondrial toxicity and HIV therapy
    SEXUALLY TRANSMITTED INFECTIONS
    
    A.J. White, "Mitochondrial toxicity and HIV therapy", SEX TRANS I, 77(3), 2001, pp. 158-173
69. Bashiardes, S; Lovett, M
    cDNA detection and analysis
    CURRENT OPINION IN CHEMICAL BIOLOGY
    
    S. Bashiardes e M. Lovett, "cDNA detection and analysis", CURR OP C B, 5(1), 2001, pp. 15-20
70. Chow, JFC; Lee, KF; Chan, STH; Yeung, WSB
    Quantification of transforming growth factor beta 1 (TGF beta(1)) mRNA expression in mouse preimplantation embryos and determination of TGF beta receptor (type I and type II) expression in mouse embryos and reproductive tract
    MOLECULAR HUMAN REPRODUCTION
    
    J.F.C. Chow et al., "Quantification of transforming growth factor beta 1 (TGF beta(1)) mRNA expression in mouse preimplantation embryos and determination of TGF beta receptor (type I and type II) expression in mouse embryos and reproductive tract", MOL HUM REP, 7(11), 2001, pp. 1047-1056
71. Gartland, M
    AVANTI 3: a randomized, double-blind trial to compare the efficacy and safety of lamivudine plus zidovudine versus lamivudine plus zidovudine plus nelfinavir in HIV-1-infected antiretroviral-naive patients
    ANTIVIRAL THERAPY
    
    M. Gartland, "AVANTI 3: a randomized, double-blind trial to compare the efficacy and safety of lamivudine plus zidovudine versus lamivudine plus zidovudine plus nelfinavir in HIV-1-infected antiretroviral-naive patients", ANTIVIR TH, 6(2), 2001, pp. 127-134
72. Rozenbaum, W; Katlama, C; Massip, P; Bentata, M; Zucman, D; Delfraissy, JF; Trepo, C; David, F; Lanier, ER; Vavro, C; Mamet, JP
    Treatment intensification with abacavir in HIV-infected patients with at least 12 weeks previous lamivudine/zidovudine treatment
    ANTIVIRAL THERAPY
    
    W. Rozenbaum et al., "Treatment intensification with abacavir in HIV-infected patients with at least 12 weeks previous lamivudine/zidovudine treatment", ANTIVIR TH, 6(2), 2001, pp. 135-142
73. Buss, N; Cammack, N
    Measuring the effectiveness of antiretroviral agents
    ANTIVIRAL THERAPY
    
    N. Buss e N. Cammack, "Measuring the effectiveness of antiretroviral agents", ANTIVIR TH, 6(1), 2001, pp. 1-7
74. Vandamme, AM; Houyez, F; Banhegyi, D; Clotet, B; De Schrijver, G; De Smet, KAL; Hall, WW; Harrigan, R; Hellmann, N; Hertogs, K; Holtzer, C; Larder, B; Pillay, D; Race, E; Schmit, JC; Schuurman, R; Shulse, E; Sonnerborg, A; Miller, V
    Laboratory guidelines for the practical use of HIV drug resistance tests in patient follow-up
    ANTIVIRAL THERAPY
    
    A.M. Vandamme et al., "Laboratory guidelines for the practical use of HIV drug resistance tests in patient follow-up", ANTIVIR TH, 6(1), 2001, pp. 21-39
75. Rusconi, S; Catamancio, SL; Citterio, P; Bulgheroni, E; Kurtagic, S; Galazzi, M; Croce, F; Moroni, M; Galli, M
    Virological response in multidrug-experienced HIV-1-infected subjects failing highly active combination regimens after shifting from lamivudine to didanosine
    ANTIVIRAL THERAPY
    
    S. Rusconi et al., "Virological response in multidrug-experienced HIV-1-infected subjects failing highly active combination regimens after shifting from lamivudine to didanosine", ANTIVIR TH, 6(1), 2001, pp. 41-46
76. Foudraine, NA; Jurriaans, S; Weverling, GJ; Burger, DM; Hoetelmans, RMW; Roos, MTL; Maas, J; Miedema, F; Reiss, P; Portegies, P; de Wolf, F; Lange, JMA
    Durable HIV-1 suppression with indinavir after failing lamivudine-containing double nucleoside therapy: a randomized controlled trial
    ANTIVIRAL THERAPY
    
    N.A. Foudraine et al., "Durable HIV-1 suppression with indinavir after failing lamivudine-containing double nucleoside therapy: a randomized controlled trial", ANTIVIR TH, 6(1), 2001, pp. 55-62
77. Van Vaerenbergh, K; Debaisieux, L; De Cabooter, N; Declercq, C; Desmet, K; Fransen, K; Maes, B; Marissens, D; Miller, K; Muyldermans, G; Sprecher, S; Stuyver, L; Vaira, D; Verhofstede, C; Zissis, G; Van Ranst, M; De Clercq, E; Desmyter, J; Vandamme, AM
    Prevalence of genotypic resistance among antiretroviral drug-naive HTV-1-infected patients in Belgium
    ANTIVIRAL THERAPY
    
    K. Van Vaerenbergh et al., "Prevalence of genotypic resistance among antiretroviral drug-naive HTV-1-infected patients in Belgium", ANTIVIR TH, 6(1), 2001, pp. 63-70
78. Kijak, GH; Pampuro, SE; Avila, MM; Zala, C; Cahn, P; Wainberg, MA; Salomon, H
    Resistance profiles to antiretroviral drugs in HIV-1 drug-naive patients in Argentina
    ANTIVIRAL THERAPY
    
    G.H. Kijak et al., "Resistance profiles to antiretroviral drugs in HIV-1 drug-naive patients in Argentina", ANTIVIR TH, 6(1), 2001, pp. 71-77
79. Squires, KE
    An introduction to nucleoside and nucleotide analogues
    ANTIVIRAL THERAPY
    
    K.E. Squires, "An introduction to nucleoside and nucleotide analogues", ANTIVIR TH, 6, 2001, pp. 1-14
80. Pillay, D
    The emergence and epidemiology of resistance in the nucleoside-experiencedHIV-infected population
    ANTIVIRAL THERAPY
    
    D. Pillay, "The emergence and epidemiology of resistance in the nucleoside-experiencedHIV-infected population", ANTIVIR TH, 6, 2001, pp. 15-24
81. Miller, V; Larder, BA
    Mutational patterns in the HIV genome and cross-resistance following nucleoside and nucleotide analogue drug exposure
    ANTIVIRAL THERAPY
    
    V. Miller e B.A. Larder, "Mutational patterns in the HIV genome and cross-resistance following nucleoside and nucleotide analogue drug exposure", ANTIVIR TH, 6, 2001, pp. 25-44
82. Miller, V
    Interpretation of resistance assay results
    ANTIVIRAL THERAPY
    
    V. Miller, "Interpretation of resistance assay results", ANTIVIR TH, 6, 2001, pp. 1-9
83. Mallal, S
    Resistance and other factors involved in therapy failure
    ANTIVIRAL THERAPY
    
    S. Mallal, "Resistance and other factors involved in therapy failure", ANTIVIR TH, 6, 2001, pp. 21-27
84. Hoetelmans, R
    Pharmacological exposure and the development of drug resistance in HIV
    ANTIVIRAL THERAPY
    
    R. Hoetelmans, "Pharmacological exposure and the development of drug resistance in HIV", ANTIVIR TH, 6, 2001, pp. 37-47
85. Kruger, WH; Jung, R; Detlefsen, B; Mumme, S; Badbaran, A; Brandner, J; Renges, H; Kroger, N; Zander, AR
    Interference of cytokeratin-20 and mammaglobin-reverse-transcriptase polymerase chain assays designed for the detection of disseminated cancer cells
    MEDICAL ONCOLOGY
    
    W.H. Kruger et al., "Interference of cytokeratin-20 and mammaglobin-reverse-transcriptase polymerase chain assays designed for the detection of disseminated cancer cells", MED ONCOL, 18(1), 2001, pp. 33-38
86. Ford, LP; Shay, JW; Wright, WE
    The La antigen associates with the human telomerase ribonucleoprotein and influences telomere length in vivo
    RNA-A PUBLICATION OF THE RNA SOCIETY
    
    L.P. Ford et al., "The La antigen associates with the human telomerase ribonucleoprotein and influences telomere length in vivo", RNA, 7(8), 2001, pp. 1068-1075
87. Makeyev, EV; Bamford, DH
    Primer-independent RNA sequencing with bacteriophage phi 6 RNA polymerase and chain terminators
    RNA-A PUBLICATION OF THE RNA SOCIETY
    
    E.V. Makeyev e D.H. Bamford, "Primer-independent RNA sequencing with bacteriophage phi 6 RNA polymerase and chain terminators", RNA, 7(5), 2001, pp. 774-781
88. Purohit, P; Dupont, S; Stevenson, M; Green, MR
    Sequence-specific interaction between HIV-1 matrix protein and viral genomic RNA revealed by in vitro genetic selection
    RNA-A PUBLICATION OF THE RNA SOCIETY
    
    P. Purohit et al., "Sequence-specific interaction between HIV-1 matrix protein and viral genomic RNA revealed by in vitro genetic selection", RNA, 7(4), 2001, pp. 576-584
89. Foxley, GL; Dong, QH; Handelsman, DJ
    Quantitative reverse transcriptase polymerase chain reaction assay for mouse androgen receptor mRNA
    ENDOCRINE
    
    G.L. Foxley et al., "Quantitative reverse transcriptase polymerase chain reaction assay for mouse androgen receptor mRNA", ENDOCRINE, 15(2), 2001, pp. 193-198
90. Wang, L; Xie, LP; Zhang, RQ
    Gene expression of gonadotropin-releasing hormone and its receptor in rat pancreatic cancer cell lines
    ENDOCRINE
    
    L. Wang et al., "Gene expression of gonadotropin-releasing hormone and its receptor in rat pancreatic cancer cell lines", ENDOCRINE, 14(3), 2001, pp. 325-328
91. Korbonits, M; Kojima, M; Kangawa, K; Grossman, AB
    Presence of ghrelin in normal and adenomatous human pituitary
    ENDOCRINE
    
    M. Korbonits et al., "Presence of ghrelin in normal and adenomatous human pituitary", ENDOCRINE, 14(1), 2001, pp. 101-104
92. Garcia-Viejo, MA; Ruiz, M; Martinez, E
    Strategies for treating HIV-related lipodystrophy
    EXPERT OPINION ON INVESTIGATIONAL DRUGS
    
    M.A. Garcia-Viejo et al., "Strategies for treating HIV-related lipodystrophy", EXPERT OP I, 10(8), 2001, pp. 1443-1456
93. Stojiljkovic, I; Evavold, BD; Kumar, V
    Antimicrobial properties of porphyrins
    EXPERT OPINION ON INVESTIGATIONAL DRUGS
    
    I. Stojiljkovic et al., "Antimicrobial properties of porphyrins", EXPERT OP I, 10(2), 2001, pp. 309-320
94. 
    Phenylthiourea compounds for treating HIV infection - Parker Hughes Institute: WO0078721
    EXPERT OPINION ON THERAPEUTIC PATENTS
    
    EXPERT OP T, 11(6), 2001, pp. 1051-1053
95. 
    Novel antiviral agents: phosphoramidates or mono/di/tri-phosphate esters of carbocyclic adenosine analogues
    EXPERT OPINION ON THERAPEUTIC PATENTS
    
    EXPERT OP T, 11(2), 2001, pp. 355-359
96. 
    Benzophenones as inhibitors of reverse transcriptase - Glaxo Group Ltd.: WO117982
    EXPERT OPINION ON THERAPEUTIC PATENTS
    
    EXPERT OP T, 11(10), 2001, pp. 1637-1640
97. Borderi, M; Verucchi, G; Tadolini, M; Spinosa, S; Fortunato, L; Talo, S; Chiodo, F
    Metabolic complications of HIV-1 antiretroviral therapy: The lipodystrophysyndrome
    MICROBIOLOGICA
    
    M. Borderi et al., "Metabolic complications of HIV-1 antiretroviral therapy: The lipodystrophysyndrome", MICROBIOLO, 24(3), 2001, pp. 303-315
98. Murray, HL; Mikheeva, S; Coljee, VW; Turczyk, BM; Donahue, WF; Bar-Shalom, A; Jarrell, KA
    Excision of group II introns as circles
    MOLECULAR CELL
    
    H.L. Murray et al., "Excision of group II introns as circles", MOL CELL, 8(1), 2001, pp. 201-211
99. Das, M; Harvey, I; Chu, LL; Sinha, M; Pelletier, J
    Full-length cDNAs: more than just reaching the ends
    PHYSIOLOGICAL GENOMICS
    
    M. Das et al., "Full-length cDNAs: more than just reaching the ends", PHYSIOL GEN, 6(2), 2001, pp. 57-80
100. Ramachandran, C; Melnick, SJ; Escalon, E; Khatib, Z; Jhabvala, P; Fonseca, HB; Smith, S; Alamo, A; Medina, S
     Cytogenetic and molecular characterization of a congenital mesoblastic nephroma
     PEDIATRIC AND DEVELOPMENTAL PATHOLOGY
     
     C. Ramachandran et al., "Cytogenetic and molecular characterization of a congenital mesoblastic nephroma", PEDIATR D P, 4(4), 2001, pp. 402-411